The Indian pharmaceutical sector is facing significant challenges following President Trump's announcement of steep tariffs on generic drug imports, which could reshape its relationship with the U.S., its largest export market.
Beginning August 1, the U.S. will maintain a 0% tariff on generic drug imports for two years, but this will escalate to 100% by August 2028 and potentially 200% thereafter if companies do not establish local manufacturing. This announcement complements earlier tariff plans on patented medicines, which also include stringent conditions for U.S. manufacturing presence.
In response, the Indian Pharmaceutical Alliance (IPA) emphasized India's role as a reliable supplier of affordable medicines to the U.S. market. The organization highlighted that Indian pharmaceutical firms operate over 40 facilities in the U.S., contributing to local jobs and investments in manufacturing and research. The IPA aims to strengthen its partnership with U.S. authorities to enhance health security for both nations.
According to the Global Trade Research Initiative, India exported $25.8 billion in pharmaceuticals globally in 2025, with $9.7 billion, or approximately 37.7%, directed to the U.S. Notably, Indian companies account for 47% of all generic prescriptions dispensed in the U.S., although they only represent about 30% of the value of U.S. generic imports. This discrepancy underscores the potential impact of the new tariffs on the Indian pharmaceutical industry’s economic viability in the U.S. market.
The impending tariff increases could lead to significant shifts in supply chains and pricing strategies, prompting Indian firms to reconsider their export strategies and possibly accelerate local manufacturing efforts to mitigate the financial impact.